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Abstract
Background: Patient-reported outcomes (PROs) are used in clinical trials to assess the effectiveness and tolerability
of interventions. Inclusion of participants from different ethnic backgrounds is essential for generalisability of cancer
trial results. PRO data collection should include appropriately translated patient-reported outcome measures
(PROMs) to minimise missing data and sample attrition.
Methods: Protocols and/or publications from cancer clinical trials using a PRO endpoint and registered on the
National Institute for Health Research Portfolio were systematically reviewed for information on recruitment,
inclusion of ethnicity data, and use of appropriately translated PROMs. Semi-structured interviews were conducted
with key stakeholders to explore barriers and facilitators for optimal PRO trial design, diverse recruitment and
reporting, and use of appropriately translated PROMs.
Results: Eighty-four trials met the inclusion criteria, only 14 (17%) (n = 4754) reported ethnic group data, and ethnic
group recruitment was low, 611 (13%). Although 8 (57%) studies were multi-centred and multi-national, none
reported using translated PROMs, although available for 7 (88%) of the studies.
Interviews with 44 international stakeholders identified a number of perceived barriers to ethnically diverse
recruitment including diverse participant engagement, relevance of ethnicity to research question, prominence of
PROs, and need to minimise investigator burden. Stakeholders had differing opinions on the use of translated
PROMs, the impact of trial designs, and recruitment strategies on diverse recruitment. Facilitators of inclusive
research were described and examples of good practice identified.
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Conclusions: Greater transparency is required when PROs are used as primary or secondary outcomes in clinical
trials. Protocols and publications should demonstrate that recruitment was accessible to diverse populations and
facilitated by trial design, recruitment strategies, and appropriate PROM usage. The use of translated PROMs should
be made explicit when used in cancer clinical trials.
Keywords: Patient-reported outcomes (PROs), Patient-reported outcome measures (PROMs), Ethnicity, Recruitment,
Cross-cultural translation, Clinical trials, Trial protocols, Primary outcomes, Secondary outcomes
Highlights
 Wide variation exists in the use of translated
patient-reported outcome measures (PROMs) in
multi-national clinical trials.
 There is a lack of transparency around publishing/
reporting ethnic group data and use of appropriately
translated PROMs.
 We identify key facilitators and barriers to using
translated culturally sensitive PROMs in cancer
clinical trials.
Introduction
Under-representation of biologically and culturally di-
verse populations in clinical trials can have implications
for the generalisability of findings to practice [1]. Studies
have shown that people from ethnic groups often have
poorer healthcare experiences and face additional bar-
riers when accessing services. Cancer incidence rates
and mortality outcomes often differ, with ethnic groups
presenting later leading to poorer health outcomes [2].
Patient-reported outcomes (PROs) are increasingly
used to evaluate primary, secondary or exploratory out-
comes in cancer clinical trials [3–5]. Patient-reported
outcome measures (PROMs) are patient-completed
measurement tools that capture PRO data and provide
the patient’s perspective on their health and impairment
status and the impact of symptoms and side effects on
their health-related quality of life (HRQoL) [6, 7].
PROMs may identify additional patient impairments,
treatment benefits, or harms that may be missed using
clinical measures alone [8–10].
Measures which reflect the patient’s health and cul-
tural experiences have been found to be more sensitive
to change and more reliable measurement tools [11, 12].
The use of translated and culturally validated PROMs fa-
cilitates the inclusion of a wider range of participants.
Culturally inappropriate PROMs may contribute to sam-
ple attrition and missing data due to misunderstood or
culturally irrelevant items, limiting the ability to estab-
lish conceptual equivalence or the wisdom in aggregat-
ing patient-centred data in clinical trial results [13].
Guidelines have been developed to ensure that transla-
tion processes are rigorous and reflect required cultural
perspectives [11, 13]. However, it is unclear if translated
and culturally validated PROMs are being used in clin-
ical trials with PRO endpoints [14] or to what extent this
guidance is being adhered to in contemporary cancer
clinical trials [4, 15].
This review aimed to establish reporting of ethnicity in
cancer trials listed on the National Institute for Health
Research (NIHR) Portfolio Database [16] and collecting
PROM data. We also reviewed whether PRO data were
captured using translated and culturally validated
PROMs. The rationale is that to meaningfully accommo-
date linguistically and culturally diverse participants,
translated and culturally validated PROMs should be
used to facilitate data collection. We also undertook
qualitative interviews with international stakeholders to
understand current practice and associated barriers and
facilitators to the use of translated and culturally vali-
dated PROMs in clinical trials [16].
Data collection
We conducted secondary data analysis of the Systematic
Evaluation of Patient-Reported Outcome Protocol Con-
tent and Reporting in Cancer Trials (EPiC) study data-
base. EPiC systematically evaluated completed cancer
clinical trials collecting a PRO as a primary or secondary
endpoint, identified on the NIHR Portfolio between
January 2001 and April 2014 [16, 17]. The most up-to-
date ethically approved trial protocol and any arising
publications were retrieved. Two independent investiga-
tors (i) extracted trial characteristics, (ii) determined the
availability of PRO results, (iii) evaluated general proto-
col and reporting quality using the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) 2013 and CONSORT (CONsolidated Standards
of Reporting Trials) checklists respectively, and (iv) eval-
uated PRO protocol content and reporting using a be-
spoke protocol checklist and the CONSORT-PRO
Extension [16, 17].
Review of protocols and publications
The current study included trials within the EPiC data-
base that included ethnicity data in their protocols and/
or publications. Two independent reviewers (KA/AS)
screened the studies for information relating to
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recruitment, inclusion/exclusion criteria, use of cultur-
ally and linguistically appropriate consent forms, infor-
mation sheets, and translated and culturally validated
PROMs, stratified by ethnicity. Disagreements were re-
solved via discussion with a third reviewer where re-
quired (MC/DK).
Qualitative study
Ethics approval was obtained from the University of Bir-
mingham Ethics Committee (ERN_17-0085A) and par-
ticipants consented to take part in interviews.
Participants were purposively sampled and had experi-
ence of PROMs, through either participation in a trial or
professional experience of designing and reviewing clin-
ical trials [16]. Participants were drawn from four
groups: (1) trialists and chief investigators with experi-
ence of cancer trials collecting a PRO as a primary or
secondary endpoint, (2) individuals with lived experience
of cancer, (3) international experts in oncology PRO trial
design, and (4) journal editors, funding panellists, and
regulatory board members [16].
Semi-structured face-to-face or telephone interviews
were conducted with individuals from the stakeholder
groups. An experienced qualitative researcher (AR) con-
ducted the interviews using a topic guide; questions re-
lating to the use of PRO and translated and culturally
validated PROMs were explored, subsequent probes
depended on the individuals’ experience. Barriers and fa-
cilitators to optimal PRO trial design, recruitment, col-
lection, and reporting, in relation to the use of translated
and culturally validated PROMs, were discussed.
Interviews were audio recorded and transcribed verba-
tim by a professional transcription service and analysed
by AR using directed thematic analysis [16]. Findings
from previous qualitative and review work, coupled with
analysis of the protocols and publications, underpinned
the development of an initial coding framework. A broad
code to extract items pertaining to the collection and
reporting of PRO data using translated and culturally
validated PROMs was used. These were coded and sub-
codes were then formulated iteratively. Formal triangula-
tion of coding was conducted by DK/MC.
Results
EPiC review results
The EPiC review identified 1141 trials across the NIHR
Portfolio Database. Of these, 228 met the eligibility cri-
teria, 160 studies had published their primary results
within the review timeframe. In total, there were 84 tri-
als for which a matching protocol and arising publica-
tion were retrieved (see Fig. 1 and Kyte et al.) [18]. Of
these 84 trials, only 14 (17%) reported any type of ethnic
group profile data (Table 1), 8 out of 14 (57%) were
Fig. 1 Study selection of cancer clinical trials using PROMs and reporting ethnic group data
Slade et al. Trials          (2021) 22:306 Page 3 of 16
Table 1 Type of trial and reporting of ethnic group profile data
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multi-national clinical trials, and the remainder were
United Kingdom (UK) based.
Reporting ethnicity
Ethnicity profile data were generally reported in relation
to baseline participant characteristics. The most fre-
quently described ethnic groups were African, African-
American, Afro-Caribbean, and Asian/Indian (Table 1).
Three trials specifically excluded non-English speakers
[29, 30, 33]. The numbers of participants represented by
ethnicity data were small (611, 13%) in comparison to
the total numbers of participants recruited across the 14
studies (4754), although in the UK this would have
reflected current population norms (Table 1). Only three
multi-national studies reported ethnicity numbers above
15% of their total population, primarily categorised as
East Asian or Asian participants (Table 1) [20, 24, 26].
One study stratified survival results by ethnicity [20].
Use of translated and culturally validated PROMs
Eight (57%) of the 14 included studies were multi-
centre, multi-national trials. The use of translated
PROMs was not reported in any of the trial protocols or
publications despite 7 (88%) using PROMs that have
been translated into other languages (Table 2). It was
not clear if missing data were related to the availability
of translated and culturally validated PROMs. One study
stated in the protocol that translated patient documents
would be available if required. However, it was not clear
if this included translated PROMs [26, 27].
Qualitative results
Forty-four interviews were undertaken with a broad
range of international stakeholders (Table 3). Issues
highlighted by the interviewees were similar despite the
diversity of professional and national backgrounds.
Three main themes emerged from the qualitative data:
(1) recruitment, (2) development of research questions
and study design, and (3) implementing translated and
culturally validated PROMs (Table 4). Key elements with
interview quotations are illustrated in Table 4. Discus-
sions relating to the use of translated and culturally ap-
propriate PROMs referred to the inclusion of
linguistically and culturally diverse participants within a
single-country trial, rather than the inclusion of inter-
national trial participants in multi-national trials, collect-
ing PROMs.
Table 1 Type of trial and reporting of ethnic group profile data (Continued)
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Table 2 PROM usage and translations available in the multi-national studies
Reference Number of sites and (number
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NS, not stated; PROM Abbreviations: BPI-SF, Brief Pain Inventory – Short Form; DAS, Diarrhoea Assessment Scale; EORTC QLQ-C30, European Organisation for
Research and Treatment of Cancer core quality of life—additional specific cancer modules include QLQ-EN24 (endometrial cancer) and QLQ-HDC29 (high-dose
chemotherapy); EQ-5D-5L, Euro-Qol quality of life questionnaire; FACIT, Functional Assessment of Cancer Therapy includes a range of measures including FACT-B
Breast Cancer module Scale, FACT-B TOI-PFB Trial Outcome Index Physical/Functional/Breast, FACIT-Fatigue Fatigue, FACT-G General, and FKSI-15 Kidney Symptom
Index-15 items; HAD, Hospital Anxiety and Depression; KPS, Karnofksy Performance Status scale; OMDQ, Oral Mucositis Daily Questionnaire; MAT, MASCC
Antiemesis Tool; MFI, Multidimensional Fatigue Inventory; RI, Rhodes Index of Nausea, Vomiting and Retching SDI-21 Social Difficulties Index; STAI-S, State Trait
Anxiety Inventory; SQLQ, Supplementary quality of life questionnaire
aReported in the paper, bstated in the protocol
Table 3 Characteristics of qualitative study participants
Interview group Total Country (n) Additional areas of expertise/experience (n)
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Methodologist (not PRO) (6), pharmaceutical experience (4)
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Journal editor (4), PRO expert (1), methodologist (not PRO) (5)
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Table 4 Research stage and themes
Research stage and themes Example quote and source
1. Recruitment
Barriers View that potential ethnic group participants are
not engaged with research
“I can walk out into the clinic and you can pretty much pick out who will not
contribute. And it’s not that they do not want to contribute, it’s that quite a lot
of the time it’s because they do not expect anyone to want them to or do not
think they can add much value.” [043]
Ineffective efforts to recruit ethnic minority
participants
“We’ve always fully intended to engage with different ethnic minority groups
and gone to lengths to see if we can have measures translated or interpreters
available but, in honesty, the vast majority of participants that we have had have
been white British and it’s not been intentional. We’ve done our work in very
mixed multicultural areas ... So we have not had to deal with that, which is odd
and I feel we should have done. I do not know what happens to those people.
And they have not been there to recruit.” [021]
Limited motivation from trialists “What we are not doing as an industry is recognising that if we go to a minority
ethnic group and say, help us do this because we need questions which are
relevant to patients from your background, they love doing it and they’ll happily
help. But generally speaking we do not do it, we assume the patient is the
patient so, you know, the white, middle class, well educated person who’s
involved gets asked the questions and then everyone wonders why you do not
get the same kind of answers from the Afro-Caribbean men or the Asian Sub-
Continent women.” [027]
Limited capacity of researchers “We did not do anything that was specifically aimed at minority groups to
increase recruitment. Our study was pretty challenging … So just getting it off
the ground … took all of our time and we did not have any bandwidth to, and
nor do I think it crossed our minds a lot either, which it should have but we just
did not have any bandwidth.” [017]
Researchers’ limited experience “No I’m aware of the fact that it’s not well done and I’m aware of the fact, some
people are trying to stress those issues, and I think it’s really important, it’s just
not something I’ve got involved with.” [013]
Fatalistic view of recruiting ethnic minority
participants
“We have to accept that minority groups are not as engaged in participating in
research studies as other groups are.” [007]
Facilitators
Understanding views and experiences of minority
groups
“There are very different views in some of our cultural groups that we have to
respect and we have to understand them to then understand what we could do
with patients at risk and what might be important and what might matter to
them.” [033]
Connecting with community leaders “You can recruit in areas where you have ethnic minority participants and
develop some engagement strategies with community leaders.” [028]
Working with peer-researchers “They had some funding … to do some research with the non-English speaking
Chinese community. And they recruited several non-English speaking Chinese …
and through interpreters worked with them and developed a structure for the
study. But then those same non-English speaking Chinese actually worked as the
researchers on the study, they actually did the field work, with support and
supervision obviously, but they actually did the field work. And the results that
came back as far as the academic team were concerned were quite unexpected
and were not typical of what they were expecting having done similar studies
with other groups of people.” [027]
Recognition that ethnic minority populations are
motivated to take part in responsible research
“But they want research done … they just want people to say what they are
collecting and why and use it responsibly and that sort of thing. I do not think it
has really held up much, there’s a lot of good research that is wanted.” [008]
2. Development of research questions and study aims
Barriers Use of international studies to identify ethnic
differences
“If you have got very different ethnic groups … the sub-section might be so
small you cannot draw any valid results from it and you can get different physio-
logical responses from different ethnic group. For instance, if you want to know
how a drug works in Chinese people, you might actually be better to do that in
China, rather than trying to allow for a small sample of ten in a much larger trial
… For drug companies … If they are going to launch something globally, they
will be testing it in China, Japan, Europe and India and they will do different trials
in each country. So, the fact that you do not necessarily test the drug in a lot of
Asian speaking people in the UK, in a way, is neither here nor there, if they are
going to do large trials in India.” [041]
Perceived relevance of ethnicity and PROs to
oncology
“I think there is a little bit less concern in oncology with the demographic make-
up of our sample. When you look at other therapeutic areas … PROs are more
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Table 4 Research stage and themes (Continued)
Research stage and themes Example quote and source
prominent and more influenced by demographic factors” [010]
Inconsistent views on relevance of ethnicity to
research question
“I think partly because [cancer type] is mainly in the Caucasian population and
not that many people - but in [large multicultural city], for example, there are a
significant number of people from the BME (Black and Minority Ethnic)
communities who do have [this kind of cancer]...” [017]
Prominence of PRO to study “I think there is a general concern with making sure that we have a very good
representative sample, but it’s not specific to PROs.” [010]
Limited detail in study protocol “It’s not typically something that really is talked about in the protocol, we will
use a validated linguistic and cultural adaptation of each instrument but there is
not any language in the protocols usually about any differences in how the
instruments are administered or anything like that … It’s just the same
procedures but same instrument in a different language.” [010]
Perceived burden upon researchers “In terms the Research Ethics Committees, there is quite a lot of debate there
about what they are indicated to do. Again, it’s about striking this balance
between what’s necessary and what’s going to place a tremendous burden on
the investigator. I think usually they are looking at the location of the research,
combined with asking, ‘Is it a disease that might specifically affect particular
groups?’ … It’s not physically possible, I think, to always ask investigators to do a
translation in every single possible language because there are just so many.”
[041]
Using English as the default language “One of our eligibility criteria was that patients had to be able to converse in
English to a high enough level to be able to complete the questionnaires.” [016]
Incompatible study design “The General Practices were randomised to be invited to [the study] … so we
did not have any choice over the practices … There wasn’t really the
opportunity to do anything different. I think if we realised at the outset that we
were not including as many ethnic minority men as we would have wished, we
might have targeted some areas with higher levels of ethnic minorities but we
did not notice that really until we looked at the final baseline figures.” [028]
Facilitators
Ensuring diversity through review process “Ethics committees are often the ones where this is discussed … and so you
might put an eligibility criteria (sic) in there which the ethics committee or
others question and say, ‘Could you broaden that out? Why does a patient need
to be able to speak English to enter the trial? Could the questionnaires be
translated?’” [016]
Design study depending on target population “Generally, also our scientific questions, you’d want those kind of geared towards
the population that you are registering. So, in a clinical trial that’s focused on
minority enrolment, our scientific questions for PROs would be geared towards
those specific populations and the issues that are important to those patient
groups but also kind of reflected in PROs that way.” [022]
Include relevant groups in study design “Researchers were told they had to go, to the minority groups who were likely
to be involved in the work. These were nursing studies by the way not major
medical treatment studies, they were told they had to go to members of the
communities and recruit them to be involved in helping define the objectives of
the study and the measures which the study was going to use. And it worked.”
[027]
Clarify recruitment aims from start “You should not change something for the PRO [or] I think this needs to be
clear from the outset so … if you have a study and you needed say three
Pakistanis and ten Indian people and five Greek then you need to state this in
the protocol so I would not feel comfortable in changing anything in the
recruitment whilst the trial is ongoing” [040]
Ensure study design can accommodate recruitment
monitoring
“It is more about the design so that the monitoring can take place on a regular
basis and be monitored continually.” [029]
3. Implementing inclusive PRO research
Barriers Researchers deviating from ethics-approved
processes
“What we said was we were going to - we did, for the purposes of the ethics
committee, if there are people who did not speak English then we would get
interpreters to interpret. And, of course, one of the good things about using the
EORTC is it’s been translated into many languages. The fact of the matter is I do
not know. I do not think we ever translated anything into another language. So
it’s a half-hearted attempt, I would say.” [017]
Unavailability of formal translations “There are trials that are done in which the PRO endpoints are not translated
into all other languages … We trust that the person who read it and talked to
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Table 4 Research stage and themes (Continued)
Research stage and themes Example quote and source
the patient and understood the question enough to interpret it in their
language.” [001]
Capacity constraints “I think it’s not so much the cost because that can be built into a trial with a
huge budget that some trials have. It’s partly to do with the time-consuming na-
ture of it. So, for instance, if some of your questionnaires have free-text responses
and those responses aren’t in English then it is time consuming to do that at a
time during the analysis when things are fairly pressured in any case. So I’m sure
it is a barrier. I’m not sure it’s purely the cost. I think it’s a bit more than that.”
[016]
Financial constraints “People say, ‘We want diversity, we want this and that’, but [sighs] I, it is a fact
that studies are very restricted in funding that … they are not able to afford
interpreters or whatever.” [036]
Administrative challenges “We did have some centres abroad … but I think the quality of life data was
more sporadic, less likely to come back from centres abroad and I think that
that’s probably an administrative thing, sending actual paper, quality of life
returns from abroad is probably more than the centres abroad could cope with.”
[014]
Reluctance of research organisations “What we found … was how using many of the common depressed mood
surveys desperately under-reported the amount of depression and depressed
mood in African American women. They tried to push [the funding body] to
allow them to use different surveys that were more appropriate, they were
newer ones though. They were not like your classic ones. They received a lot of
pushback back then. That was early mid-90s and they said, ‘No, these are the
ones you use’.” [011]
Facilitators
Pilot PRO instruments with target populations “Within our regular clinical trials, when we do a PRO component it is
administered to all patients, including minorities. We have specifically targeted
minorities for a couple of our studies. We’ve done a couple of feasibility studies
for our new, newer, questionnaires … We did an enrichment strategy where we
were purposefully trying to enrol minority folks because they are generally
underrepresented on our clinical trials. And so to make sure that our tools and
our message were applicable across a wide range of the population we did kind
of purposefully try to enrol as many as minorities as we could.” [022]
Undertake research in diverse localities “The minority representation should be a consideration and I would think in
large urban settings, there are numerous minorities and that would be a good
base upon which to recruit minorities.” [029]
Monitor recruitment and address shortcomings in
real time
“That could be a nurse practitioner, a member of the investigative staff. A
concerted effort. Maybe they’ll say “Well we do not have enough representation
with respect to minorities. What can we do to reach out?” So maybe having a
member of the investigative team who is also a minority may reach out to
fellow minorities in order to make Patient Reported Outcomes more accessible
to minorities … [Monitoring] with military precision.” [029]
Research Ethics Committees requesting details
pertaining to diverse involvement
“We just require them to tell us to what extent they are validated in other
languages. Or if we are going to translate … we always want that spelled out
and it’s incredible how researchers … think they can just use any old online
translation tool and that’s sufficient for something as important as research tools
and not do any of the proper cognitive testing and more rigorous validation of
their tools in other languages … When there’s these multiple language or
cultural barriers, particularly language though, people look out for how are they
being delivered, can they be conducted orally. Does the person, the participant
themselves always have to fill it out? What about their care giver or close family
member, can they sit down with them and tell them what to do?” [008]
Signalling from research organisations of
importance of diverse trial participation
“I guess, unlike PPI [Patient and Public Involvement], for instance, they might not
have as high a profile in the [funder’s] materials. PPI, there’s sections on it in the
application where you have to say what you are doing, how you are going to
pay for it, etc., etc., whereas there is not, I do not think, quite the same level of
emphasis on how you are going to make sure those people who are in your trial
actually represent the patients with whatever condition it is that you are
interested in. So maybe more emphasis … might nudge people to do a better
job.” [016]
Tying diversity targets to funding “At [national research organisation] actually, you have to have a plan as to how
you are going to include minorities and women and that has to be signed off
on. If it’s not agreed to, you do not get your money and then you have to
report annually on how you are doing.” [011]
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Theme 1: Recruitment
Several participants identified challenges regarding the
recruitment of ethnically diverse samples within the
countries in which the trials operate. They described the
lack of resources for recruitment and inclusive recruit-
ment strategies as flaws in the trial design and a barrier
to recruitment.
Some participants were pessimistic, stating that certain
communities were wary of engaging with research
(Table 4); however, it was considered that dynamic and
flexible recruitment methods would overcome this. Par-
ticipants described how communities are often receptive
to efforts by researchers to meaningfully engage and bet-
ter understand research priorities and concerns; this
may be through working with community leaders and
using peer-researchers. However, interviewees acknowl-
edged that their recruitment efforts were sometimes in-
effective, and more effort could be made to design better
recruitment strategies when engaging with ethnically di-
verse groups. Participants also described how unsuccess-
ful attempts to recruit diverse samples often meant that
translated and culturally validated PROMs were ren-
dered unnecessary.
Theme 2: Development of research questions and study
design
The rationale and feasibility for a cancer clinical trial to
purposively sample based on ethnicity and the impact
on subsequent trial design was discussed. Participants
described the incidence of cancer by ethnicity and ques-
tioned whether ethnicity was a necessary factor for ex-
ploration in these trials. It was considered that if
participant samples were representative of the general
population, there was no need to stratify results by
ethnicity.
Participants described the extent to which translated
and culturally validated PROMs were considered during
the trial design process (and detailed in the protocol).
This depended on the prominence of the PRO within
the study and whether targeted recruitment of specific
groups was compatible with the study design. It was also
noted that fluency in English is often used as an eligibil-
ity criterion for PRO components. Participants described
using English as the default language and this was
considered standard practice in many studies, rendering
the use of translated and culturally validated measures
unnecessary.
Concerns were voiced about balancing the need for in-
clusivity without additionally burdening the investigator.
However, participants also described how research ques-
tions formulated with consideration of the target popula-
tion promotes the use of study design and PRO strategy
that is appropriate and reflects the priorities of the
groups. Nursing studies were given as examples of good
practice in this regard, whereby researchers engaged ac-
tively with target populations to recruit community
members to define study objectives and oversee the se-
lection of measures. Participants described experiences
of research ethics committees ensuring that eligibility
criteria were not arbitrarily restrictive and ensuring trial
designs accommodated the monitoring of recruitment to
ensure a diverse sample was captured during trials.
Theme 3: Implementing inclusive PRO research
A recurring theme was the difficulty of ensuring trans-
lated and culturally validated PROMs were available and
the time-consuming, expensive, labour-intensive nature
of their use. One participant described how uptake of
new measures that are validated with population sub-
groups can be undermined by the preference for older,
more commonly used measures. Another explained how
inclusive PRO strategies detailed in ethics committee ap-
plications may not be implemented in practice. One par-
ticipant reported having used translated PROMs in
other studies; however, we were unable to identify evi-
dence of similar practices in any of the protocols or trial
publications in our sample. Administrative difficulties
and capacity restraints involved in collecting different
versions of PROMs in multi-national trials were consid-
ered challenging. Where translations were not available,
it was suggested researchers were dependent on transla-
tions of the questions by the recruiter for the partici-
pants. Several facilitators of inclusive PRO research were
described. It was suggested that recruitment aims should
be clear at the beginning of the design process and mon-
itored throughout the study in real time to ensure a rep-
resentative sample; making use of existing instruments
that have been extensively translated and validated;
Table 4 Research stage and themes (Continued)
Research stage and themes Example quote and source
Availability of pre-translated PRO measures “With different ethnicities obviously it all boils down to the language and feeling
comfortable enough with the language and understanding the questionnaire,
we have been working with the EORTC with the PROs and quality of life
questionnaires in different countries because these are multi-national studies so
we have translations of those PROs in the different languages and in some coun-
tries they used the local language and English and maybe a second or third or
fourth language, so this can be done.” [040]
PRO patient-reported outcome
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piloting PROMs with the target community groups,
adopting an “enrichment” strategy to promote recruit-
ment; and recruitment in diverse localities. Participants
described the role of key research institutions and sug-
gested ethics committees could request details pertaining
to diverse recruitment and diversity targets could be
linked to funding. Thus, following successful examples,
such as that of Patient and Public Involvement (PPI) ini-
tiatives, enables diverse trial participation in clinical
trials.
Discussion
In this review, we identified the extent to which ethnicity
was reported in a cohort of cancer clinical trials and
whether translated and culturally appropriate measures
were used to capture PRO data. We examined the bar-
riers and facilitators to using appropriate PROMs with
ethnically diverse groups. Several findings emerged (Fig.
2). First, few trials reported the collection of data by eth-
nic groups despite many of the studies being multi-
centred and multi-national. Second, no trials including
the multi-national studies reported using translated
PROMs. Third, qualitative interviews highlighted signifi-
cant barriers to the use of translated and culturally vali-
dated PROMs, including availability of measures,
insufficient resources and training, investigator burden,
and administrative difficulties associated with collecting
different versions.
The dearth of reporting in both protocols and publica-
tions raises several issues and questions: firstly, the ex-
tent to which patients are excluded because of language/
cultural barriers is not transparent, and secondly, failure
to report the use of translated and culturally validated
PROMs. This has a number of important implications
for cancer clinical trials.
Recruitment
Where ethnicity data was reported, it was generally in
relation to baseline characteristics. Most studies did
not report ethnicity data, this may be due to small
numbers being recruited or because it was not con-
sidered necessary to report this information. Eight of
the included studies were multi-national, yet numbers
reported for ethnicity were still low in comparison to
the overall number recruited. Only three multi-
national studies recruited more than 15% from identi-
fied ethnic groups, and these were made up of pre-
dominantly East Asian and Asian populations.
Interviewees identified a number of barriers including
design and recruitment issues, limited time, training
and resources, and staff preconceptions about recruit-
ing ethnic group participants.
Development of research questions and study design
Respondents in the qualitative interviews raised several
issues relating to the research design and study aims.
Participants had differing views on whether stratification
by ethnicity was relevant if samples were representative
of the population. Trial designs can contribute to sample
attrition and lack of transparency in relation to data col-
lection and analysis. The recent development of the
SPIRIT-PRO guidelines for trial protocol writers should
help improve the design and transparency of clinical tri-
als with a PRO element, ensuring future clinical trials
will be more transparent and rigorously designed [35].
It was suggested that pre-testing of PROMs with eth-
nic groups during the development phase might identify
potential translation issues and facilitate recruitment.
Examples of successful facilitation of ethnic group re-
cruitment included the use of peer-researchers and en-
gagement with ethnic groups and community leaders.
Implementing inclusive PRO research
Studies have shown that PROMs provide a rich source
of data and, alongside clinical data, can identify adverse
events and the impact of therapeutics on quality of life
[36]. Side effects of treatments may have a negative im-
pact on quality of life. It is important these effects are
captured for all participants, via their access to linguis-
tically translated and culturally validated PROMs, pre-
venting additional issues and potentially improving
survival outcomes [37, 38]. PROM data can then be used
to assess the benefit-risk assessment for all patients in
regulatory labelling claims [5, 39].
Details of administration and use of culturally relevant
PROMs in the protocols or publications were limited.
Identified barriers included uncertainty about which
translations would be required, difficulties with adminis-
tration, and time and resources required to translate and
utilise culturally validate PROMs. Availability of trans-
lated and culturally validated PROMs was a concern
raised in some of the interviews. However, most of the
studies in this review used measures such as the
EORTC-C30, which has a wide range of validated trans-
lated versions and is freely available [13, 15]. Whilst ad-
ministration of different versions can be complex, details
of their implementation should be reflected in the proto-
col [4]. There was no indication that translated versions
were being used in the studies, one study stated that
translated patient documents were available if required,
but it was not clear if this included the PROMs. One
participant in the interviews intimated that translated
PROMs were being used but not reported in protocols
or papers. Another suggested that even if it was stated
that translations would be used it did not necessarily
happen in practice.
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Using culturally insensitive PROMs can add to attri-
tion rates and high levels of missing data. Many re-
searchers assume it is sufficient to use a linguistically
validated PROM without ensuring cross-cultural
equivalence [40]. Recent recommendations to ensure
cross-cultural validity are important to consider when
adapting PROMs [4, 13, 15, 41]. If data is being
pooled from different translations, it is important to
establish conceptual and psychometric equivalence of
data and this should be transparent in protocols and
publications [40, 41]. Psychometric validation of
cross-cultural equivalence can be costly and time con-
suming to achieve [40]. There is also an issue around
the sample sizes required to evaluate cross-cultural
equivalence [4, 40]. This may not be feasible in all
cancers, especially rarer forms [42]. Another concern
is the suggestion that researchers administering the
PROM are translating questions for participants. This
could potentially invalidate the data, and methods of
administration should be made explicit in the proto-
col, as recommended by the SPIRIT-PRO extension
guidelines [35].
Fig. 2 Resources required and barriers and facilitators to engaging with ethnic group participants in clinical trials
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Recent studies have demonstrated that the inclusion
and implementation of PRO data in clinical trials is gen-
erally poor, and PRO data results are often not published
[37]. We can only identify the differences or advantages
of therapeutic options by assessing the therapeutic im-
pacts of cancer treatments on quality of life and symp-
toms for all participants. The additional issues relating
to exclusion of some participants either by design or by
default threaten the external validity of clinical trials.
This study has demonstrated that reporting of ethni-
city data in relation to PRO in clinical trials was limited,
and transparency around the use of translated PROMs
needs addressing. The SPIRIT-PRO extension provides
international consensus-based guidance on protocol
content for clinical trials including PRO. Use of these
guidelines moving forward may improve the overall de-
tail of trial protocols in relation to PRO data collection
and administration. Indeed, some of the issues raised in
discussion with stakeholders are addressed by many of
the SPIRIT-PRO guidelines [35]. These include the im-
portance of specifying PRO-specific language require-
ments, domains and concepts being used, sample size
requirements for PRO endpoints, administration of
PROMs, and whether more than one language version is
being used [35]. PRO analysis plans may require adjust-
ments based on ethnicity, with specific mention to in-
clude reference to exclusion or inclusion on the basis of
language, and reporting of ethnicity data [35].
Reviewers and funders may need to be more cognisant
about the use of translated and culturally validated
PROMs especially when trials being reviewed are multi-
national. More transparency in the reporting of trials
may also help judgements to be made on the applicabil-
ity of clinical trials to all populations, thus helping to re-
duce health inequalities [43]. Research ethics
committees could also provide a steer on the recruit-
ment of ethnic groups and the use of translated PROMs,
when reviewing clinical trial protocols. Ensuring trans-
parency of recruitment procedures in relation to ethnic
groups and monitoring recruitment and use of transla-
tions might also facilitate better engagement with ethnic
group communities and the use of translated PROMs in
the future.
This study is not without limitations. The review was
reliant upon clinical trial protocols and publications
based in an English-speaking country, and therefore, the
use of English is standard as key sources of information
pertaining to the operations and processes within the
trial sample. The lack of transparency around the use of
culturally and linguistically validated PROMs in the
multi-national trials demonstrates a concerning pattern
of non-inclusion of international trial participants in
PRO components of clinical trials. A limitation of the
qualitative component was that discussion largely related
to the use of translated and culturally appropriate
PROMs in the inclusion of linguistically and culturally
diverse participants within a single-country trial, rather
than the inclusion of international trial participants in
multi-national trials, collecting PRO data. This may be
an area to consider for future research.
Strengths of this study include the use of both an
evaluation of trial protocols and publications and quali-
tative interviews with international stakeholders. Reviews
of the protocols and publication identified the current
state of play regarding recruitment and the use and
reporting of translated and culturally validated PROMs
in cancer clinical trials. Qualitative interviews allowed an
in-depth exploration of the existing issues, as perceived
by a range of international stakeholders.
Conclusions
Cancer clinical trials should be transparent in their re-
cruitment strategies and demonstrate that recruitment is
accessible to all representative populations and facili-
tated by the trial design, recruitment strategies, and the
use of translated and culturally validated PROMs. Trans-
parency in reporting and use of culturally as well as lin-
guistically adapted PROMs needs to be demonstrated.
Where data from different translated versions are aggre-
gated, the validity of this approach should be demon-
strated, including information around psychometric
equivalence. The current level of reporting makes it dif-
ficult to quantify precisely the shortcomings in this area
due to widespread omissions in reporting of ethnicity
data and the use of translated and culturally validated
PROMs in trial protocols and publications.
Funding bodies and research reviewers should con-
sider the access of trial participants to appropriate
PROMs. Reviewers and journal editors need to be aware
of the need for appropriate reporting on the use of
translated and culturally validated PROMs in multi-
national clinical trials. Future use of the SPIRIT-PRO
guidelines may help prevent some of the omissions seen
in the current use and reporting of appropriately trans-
lated PROMs. Increasing the transparency of PROM
usage in future clinical trial reports and protocols will
enable us to identify the extent to which cancer clinical
trials are inclusive and patient centred.
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